MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ

Real-time Quotes | Nasdaq Last Sale

67.74
+1.60
+2.42%
Opening 13:07 05/26 EDT
OPEN
66.04
PREV CLOSE
66.14
HIGH
69.31
LOW
66.04
VOLUME
116.33K
TURNOVER
5.84M
52 WEEK HIGH
119.38
52 WEEK LOW
52.33
MARKET CAP
1.16B
P/E (TTM)
-4.6225
1D
5D
1M
3M
1Y
5Y
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will par...
GlobeNewswire · 05/17 12:00
--Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $170 From $180, Maintains Outperform Rating
MT Newswires · 05/10 10:13
BRIEF-Madrigal Pharmaceuticals Inc Says On May 9, Entered Into A Loan And Security Agreement
reuters.com · 05/09 16:20
Madrigal Announces Debt Funding Of $250M To Back Potential US Resmetirom Launch
Benzinga · 05/09 14:14
We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 05/09 13:45
Madrigal Pharmaceuticals Q1 EPS $(3.36) Beats $(3.62) Estimate
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.36) per share which beat the analyst consensus estimate of $(3.62) by 7.18 percent. This is a 1.2 percent decrease over losses of $(3.32) per share
Benzinga · 05/09 10:41
Recap: Madrigal Pharmaceuticals Q1 Earnings
  Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/09 10:40
Madrigal Pharmaceuticals GAAP EPS of -$3.36 beats by $0.20
Madrigal Pharmaceuticals press release (NASDAQ:MDGL): Q1 GAAP EPS of -$3.36 beats by $0.20. As of March 31, 2022, Madrigal had cash, cash equivalents and marketable securities of $220.0 million, compared
Seekingalpha · 05/09 10:32
More
No Data
Learn about the latest financial forecast of MDGL. Analyze the recent business situations of Madrigal Pharmac through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

30.77%Strong Buy
61.54%Buy
0.00%Hold
7.69%Under-perform
0.00%Sell
Analyst Price Target
The average MDGL stock price target is 161.67 with a high estimate of 203.00 and a low estimate of 129.00.
High203.00
Average161.67
Low129.00
Current 67.74
EPS
Actual
Estimate
-3.12-2.34-1.56-0.78
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 208
Institutional Holdings: 12.50M
% Owned: 73.08%
Shares Outstanding: 17.10M
TypeInstitutionsShares
Increased
42
709.50K
New
28
804.96K
Decreased
42
445.56K
Sold Out
15
133.62K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.23%
Pharmaceuticals & Medical Research
+0.39%
Key Executives
Chairman/Chief Executive Officer/Director
Paul Friedman
Chief Financial Officer
Alex Howarth
Corporate Executive/Director
Rebecca Taub
Senior Vice President/General Counsel
Brian Lynch
Senior Vice President
Dominic Labriola
Senior Vice President
Remy Sukhija
Lead Director/Independent Director
Frederick Craves
Independent Director
Kenneth Bate
Independent Director
James Daly
Independent Director
Keith Gollust
Independent Director
Richard Levy
Independent Director
David Milligan
No Data
No Data
About MDGL
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The Company’s lead product candidate, MGL-3196 (resmetirom), is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of non-alcoholic steatohepatitis (NASH)and heterozygous familial hypercholesterolemia (HeFH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and HeFH.

Webull offers kinds of Madrigal Pharmaceuticals Inc stock information, including NASDAQ:MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.